NeoStem Secures Debt Facility
No warrants or common stock were issued in connection with this financing. “This new debt facility will serve as an excellent source of non-dilutive capital to support the launch of our Intus Phase 3 clinical trial in metastatic melanoma, a significant …
After subscribing to the service (All Levels) this menu will become active to direct you to member database locations and weekly audio recordings. Please refresh the page if you have subscribed and are still seeing this message.